We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
-2.33%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$244M
AUM Growth
-$11.8M
(-4.6%)
Cap. Flow
+$12.7M
Cap. Flow
% of AUM
5.19%
Top 10 Holdings %
Top 10 Hldgs %
62.11%
Holding
67
New
30
Increased
14
Reduced
7
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$15.1M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
+$11M |
| 3 |
Guardant Health
GH
|
+$9.53M |
| 4 |
Eli Lilly
LLY
|
+$8.42M |
| 5 |
Edwards Lifesciences
EW
|
+$7.85M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$15M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
+$11.3M |
| 3 |
Protagonist Therapeutics
PTGX
|
+$9.3M |
| 4 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
+$9.06M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$8.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.84% |
| 2 | Consumer Staples | 4.83% |
| 3 | Industrials | 0.1% |
| 4 | Real Estate | 0.04% |
| 5 | Materials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Adicet Bio
ACET
$85.2M
| $2.68M | 1.1% |
11,491
-21,213
| -65% | -$4.66M |
|
27
Evolus
EOLS
$385M
| $2.53M | 1.03% |
+217,767
| New | +$2.57M |
|
|
SNCE
28
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $2.08M | 0.85% |
+51,810
| New | +$3.78M |
|
29
X4 Pharmaceuticals
XFOR
$375M
| $1.68M | 0.69% |
57,943
+690
| +1% | +$26.2K |
|
30
Amylyx Pharmaceuticals
AMLX
$2.26B
| $1.55M | 0.63% |
+80,459
| New | +$955K |
|
|
31
CALL
Protagonist Therapeutics
PTGX
$8.79B
| $1.23M | 0.5% |
+155,000
| New | +$1.87M |
|
32
3M
MMM
$90.9B
| $210K | 0.09% |
+1,936
| New | +$234K |
|
33
Femasys
FEMY
$8.64M
| $202K | 0.08% |
4,192
-206
| -5% | -$6.96K |
|
34
Annaly Capital Management
NLY
$17.1B
| $104K | 0.04% |
4,417
+402
| +10% | +$10.4K |
|
35
Transocean
RIG
$5.89B
| $66K | 0.03% |
+19,683
| New | +$79.8K |
|
|
ALLK
36
DELISTED
Allakos
ALLK
| $63K | 0.03% |
+20,029
| New | +$74.8K |
|
37
NovaGold Resources
NG
$2.56B
| $55K | 0.02% |
+11,433
| New | +$71.4K |
|
38
Shattuck Labs
STTK
$675M
| $54K | 0.02% |
+13,230
| New | +$47.9K |
|
39
AvePoint
AVPT
$2.76B
| $53K | 0.02% |
+12,140
| New | +$61.6K |
|
40
Nektar Therapeutics
NKTR
$2.39B
| $51K | 0.02% |
+893
| New | +$56.3K |
|
41
CEL-SCI Corp
CVM
$20.3M
| $50K | 0.02% |
+374
| New | +$39K |
|
42
Advantage Solutions
ADV
$522M
| $46K | 0.02% |
+486
| New | +$58.7K |
|
|
LEV
43
DELISTED
The Lion Electric Company
LEV
| $44K | 0.02% |
+10,466
| New | +$61.4K |
|
44
Wheels Up
UP
$208M
| $39K | 0.02% |
+99
| New | +$52.9K |
|
45
Skillsoft
SKIL
$63.7M
| $38K | 0.02% |
+545
| New | +$56.2K |
|
|
ME
46
DELISTED
23andMe Holding Co
ME
| $36K | 0.01% |
+718
| New | +$41.6K |
|
47
Aligos Therapeutics
ALGS
$26.2M
| $35K | 0.01% |
+1,172
| New | +$39.8K |
|
|
GATO
48
DELISTED
Gatos Silver, Inc.
GATO
| $35K | 0.01% |
+12,062
| New | +$42.4K |
|
49
Aveanna Healthcare
AVAH
$2.04B
| $34K | 0.01% |
15,151
+4,303
| +40% | +$12.5K |
|
|
MKFG
50
DELISTED
Markforged Holding Corporation
MKFG
| $33K | 0.01% |
+1,759
| New | +$51.4K |
|
Similar funds
DCM
AMPWP
DCM
IWP
PCS
ACGDR
GEA
ECM
Tri Locum Partners's Q2 2022 Portfolio in Review
As of Q2 2022, Tri Locum Partners held 67 positions worth $244M, down 4.6% from $256M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Tri Locum Partners deployed $12.7M of net new capital in Q2 2022, opening 30 new positions and adding to 14 existing holdings. Its largest new stake was CATALENT, INC.: 108,241 shares worth $11.6M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 93% a quarter earlier, followed by Consumer Staples and Industrials.
On the sell side, the largest reduction was Jazz Pharmaceuticals, an estimated $11.3M trimmed.
- Tri Locum Partners's largest Q2 2022 buy was CATALENT, INC.: 108,241 shares worth $11.6M.
- Tri Locum Partners added most to argenx in Q2 2022, an estimated $15.1M increase.
- Tri Locum Partners's biggest Q2 2022 reduction was Jazz Pharmaceuticals, cutting an estimated $11.3M.
- Tri Locum Partners fully exited Regeneron Pharmaceuticals in Q2 2022, selling an estimated $15M.
- Tri Locum Partners's ten largest holdings make up 62% of its $244M portfolio in Q2 2022.
- Tri Locum Partners opened 30 new positions and closed 16 in Q2 2022.
- Tri Locum Partners's portfolio value fell 4.6% quarter-over-quarter to $244M.
Based on Tri Locum Partners's 13F filing for Q2 2022, filed 15 Aug 2022.